Efficacy of A Novel in Prevention of Neonatal Hypothermia
Launched by ISTANBUL UNIVERSITY - CERRAHPASA · Feb 6, 2023
Trial Information
Current as of August 11, 2025
Completed
Keywords
ClinConnect Summary
Although neonatal hypothermia has higher rates especially in underdeveloped and developing countries, it is a global health problem also seen in developed countries. In a meta-analysis study, the prevalence of neonatal hypothermia was reported as 57.2% in East Africa. In a multicenter, prospective study, 79.6% of preterm newborns were admitted to NICUs with hypothermia in Ethiopia. In a study, the incidence of hypothermia to be 53% in the first 24 hours of life in preterm infants they conducted in a hospital in France. In a study, in 28 countries with upper-middle income status, admission t...
Gender
ALL
Eligibility criteria
- • Inclusion Criteria: Preterms;
- • between 32-37 GH,
- • with an indication for hospitalization in the NICU,
- • with a body temperature of 36.4 °C and above in the axillary route immediately after birth,
- • with a maternal body temperature between 36.4 °C and 38 °C in the tympanic route are included in the study
- • Exclusion Criteria: preterms;
- • with congenital anomalies,
- • who were transported to another hospital, or who were transported to the hospital where the research was conducted from an external center
About Istanbul University Cerrahpasa
Istanbul University - Cerrahpasa is a prestigious academic institution renowned for its commitment to advancing medical research and education. With a focus on innovative clinical trials, the university harnesses cutting-edge methodologies to address pressing health challenges. Its collaborative environment fosters interdisciplinary research, enabling the development of effective therapeutic strategies and enhancing patient care. The institution's dedication to ethical standards and patient safety underscores its reputation as a leader in clinical research within the region and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Istanbul, , Turkey
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials